Undetectable levels of HCV RNA can be found in LT candidates secondary to pharmacologic treatment or spontaneous clearance. An understanding of the post-transplant HCV disease progression and recurrence in this population

is still limited. The aim of this study was to investigate the outcomes of LT patients that were HCV antibody positive, but had undetectable HCV RNA at the time of transplant. Methods: A total of 22 patients were found to have undetectable HCV RNA at transplant. Fifteen of these patients received pre-LT anti-viral therapy, of which 9 achieved a sustained virologic response, while spontaneous clearance of HCV was observed in 7 patients. Virologic and histologic recurrence, and overall PS-341 manufacturer survival find more were set as endpoints. Results: Post-LT virologic recurrence occurred in 36% (8 of 22). The rates of histological recurrence (stage 2 or greater fibrosis) at 1-year and 3-years were 29% and 44%, respectively, which was comparable to patients in the pre-transplant detectable HCV RNA group (n =162) (p = 0.31). Advanced fibrosis (stage 3 and 4) occurred in 3 of 22 patients,

and no graft loss or mortality secondary to HCV recurrence was observed in the pre-LT undetectable HCV RNA group. Conclusion:

The results of this study suggested that, although virologic recurrence was lower, undetectable HCV Avelestat (AZD9668) RNA prior to transplant did not necessarily led to an increase in recurrence free time or patient survival. Comparison of histological recurrence and of HCV and overall survival between the detectable and undetectable HCV RNA before liver transplantation. (A) Endpoint as stage 2-4 fibrosis recurrence (F2-4) (p = 0.31). (B)Overall survival (p =0.36). Disclosures: Kimberly Ann Brown – Advisory Committees or Review Panels: CLDF, Merck, Salix, Gilead, Vertex, Novartis, Genentech, Gilead, Janssen, Novartis, Salix; Consulting: Blue Cross Transplant Centers, Salix; Grant/Research Support: CLDF, Gilead, Exalenz, CDC, BMS, Bayer-Onyx, Ikaria, Hyperion, Merck; Speaking and Teaching: Salix, Merck, Genentech, Gilead, CLDF, Vertex The following people have nothing to disclose: Shunji Nagai, Gabriel Schnickel, loannis Theodoropoulos, David A. Bruno, Marwan Kazimi, Atsushi Yoshida, Marwan S.